Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts (original) (raw)
Figure 5
Pharmacokinetic analysis of VCR, DEX and ASP in leukemias bearing NOD/SCID mice.
Engrafted female mice (ALL-19) were treated with VCR (0.15 mg/kg), DEX (5 mg/kg), ASP (1000 U/kg) or their combination (VXL) at the same doses. Three mice each were sacrificed at specified time points and drug concentrations in plasma for VCR (A); DEX (B); and ASP (C) in the single agent or combination treatment were assessed as described in Materials and Methods.